gila monster glp 1 The + GLP-1: How a Lizard Changed Medicine From Gila Monster to GLP-1

2025;gutjnl-2024-332891

Masuho, I., Skamangas, N

article/pii/S0140673624014983 [Additional references continue covering all cited sources from the searches conducted] [1] Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial ScienceDirect science/article/pii/S0140673624014983 [2] The SELECT trial of semaglutide in patients with overweight or obesity without diabetes: establishing a new pathway to secondary prevention of cardiovascular disease PubMed pubmed.ncbi.nlm.nih.gov [3] Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial PubMed pubmed.ncbi.nlm.nih.gov [4] Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial PubMed pubmed.ncbi.nlm.nih.gov [5] GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)

Another study found a 0.83% overall risk of these events in GLP-1 RA users compared to a 0.63% overall risk of these events in non-GLP-1 RA controls (Bloomgarden 2024)

Constant exposure can downregulate these receptors, requiring higher doses for the same effect